Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual of tumour.
Epistemonikos ID: 2e201a034353fd538b49d0feaeaecefe7bb1da62
First added on: May 22, 2024